Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, December 9 at 2:00 PM ET

Register Free →

This Solicitation opportunity from Department Of Defense was posted on October 17, 2025. The submission period has ended. Browse the details below for market research, or find similar active opportunities.

Smart Red Blood Cells (Smart-RBC)

Closed
DARPA-PS-26-02Federal

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

Active Opportunities Like This One

NAICS: 541714
New
Federal
Chemical, Biological, Radiological, and Nuclear (CBRN) Medical Countermeasure (MCM) Participant Basic Agreement (PBA)
Solicitation # W911SR-26-R-HEAL
The Capability Program Executive for Chemical, Biological, Radiological, and Nuclear Defense (CPE CBRND) is establishing the Chemical, Biological, Radiological, and Nuclear (CBRN) Medical Countermeasure (MCM) Participant Basic Agreement (PBA) ecosystem. This continuous, open announcement seeks to build a network of pre-qualified partners to accelerate the development, testing, and fielding of next-generation medical defense solutions. The program focuses on two primary pillars: host-targeted resilience, which targets critical host systems like neurological and respiratory pathways to enhance physiological protection, and threat-targeted neutralization, which focuses on broad-spectrum countermeasures for prophylaxis and acute treatment. Priority is given to candidates designed for austere environments, featuring environmental stability without cold-chain reliance and simplified administration routes such as oral or intranasal delivery. The government is inviting two types of participants: MCM Development Collaborators, ranging from Phase I products through FDA licensure, and MCM Development Support Collaborators, such as CROs and CDMOs specializing in preclinical testing, cGMP manufacturing, and regulatory submissions. Interested parties must submit a white paper of no more than five pages detailing their product descriptions, efficacy data, regulatory status, and manufacturing capabilities. Acceptance into the PBA enables the subsequent award of project orders under the authority of 10 U.S.C sections 4021, 4022, and 4023. These agreements are not subject to the Competition in Contracting Act of 1984. All prospective awardees must be registered in the System for Award Management (SAM) database to receive payment.
W6QK Acc-Apg

POSTED

about 11 hours ago

DEADLINE

N/A
NAICS: 541714
New
Federal
DNA Sequencing Service
Solicitation # 75N98027Q00090
The National Institutes of Health (NIH) is soliciting a Firm Fixed-Price Indefinite Delivery/Indefinite Quantity (IDIQ) contract for high-throughput DNA sequencing services, including Sanger DNA sequencing and whole-plasmid sequencing. The scope of work involves processing plasmid DNA, genomic DNA, and PCR-generated material, with requirements for PCR amplification, product purification, and DNA normalization. The contractor is responsible for providing all sample collection and shipping materials, maintaining strict confidentiality of sequencing data, and retaining DNA samples for at least 180 days post-sequencing. Deliverables include specific electronic file formats such as .ab1, .fasta, and raw FASTQ data, alongside a Monthly Status Report submitted to the Contracting Officer's Representative (COR). The contract spans a five-year period from January 4, 2027, to January 3, 2032, with a total estimated value ranging from $184,200.00 to $958,584.20. Performance and delivery are centered at the NIEHS facility in Research Triangle Park, North Carolina. Award selection will be based on a best value tradeoff, where technical capability and past performance are weighted more heavily than price. Technical evaluations will focus on sequencing capability, personnel qualifications, quality assurance/control, and data management. The acquisition is not set aside for small businesses and falls under NAICS code 541714.
National Institutes Of Health Olao

POSTED

about 11 hours ago

DEADLINE

in 20 days
NAICS: 541714
New
Federal
FY27 FDA Broad Agency Announcement (BAA) for Advanced Research and Development of Regulatory Science
Solicitation # FDABAA-27-00123
The FY27 FDA Broad Agency Announcement (FDABAA-27-00123) solicits basic and applied research and development proposals to advance regulatory science and innovation. Managed by the FDA Office of Acquisitions and Grants Services, this solicitation is open to all responsible sources, including small businesses and academic institutions. The program focuses on 22 priority research areas, with recent updates adding specific interests in human tooth enamel evaluation techniques for anticaries dentifrice products and the adoption of Super Intelligence terminology in tobacco and nicotine research per Executive Order 14434. Interested parties must follow a two-tiered submission process consisting of a three-page concept paper and a comprehensive full proposal, which includes a technical volume limited to 50 pages and a detailed cost proposal. All applications must be submitted as searchable PDFs via email by January 22, 2027, at 5:00 PM EST. A virtual BAA Day is scheduled for December 8, 2026, to provide guidance on the application process and FDA priorities. Awards are based on the overall best value to the government, evaluated through a high-level relevance review followed by a technical review by subject matter experts. Successful offerors must comply with Good Manufacturing Practice Regulations (21 CFR Parts 210-211) and other relevant biological or diagnostic standards. Additionally, proposals exceeding $900,000 from non-small businesses require a Small Business Subcontracting Plan. Contractors must also warrant the absence of organizational conflicts of interest and adhere to strict data disclosure and privacy regulations.
FDA Office Of Acq Grant Svcs

POSTED

1 day ago

DEADLINE

in 2 months
NAICS: 541714
New
Federal
Presolicitation Notice to Sole Source for Experimental Pathology Laboratories, Inc. (EPL)
Solicitation # Presolicitation_NOI_Sole_Source_EPL
The U.S. Environmental Protection Agency, through the Office of the Chief Procurement Officer's Water, Tribal, and Science Division, intends to award a firm-fixed price purchase order for histology and pathology services of maternal and neonatal rodent specimen organs. The work will be performed at the EPA Headquarters in Washington, DC, and focuses on the toxicologic pathology of environmental contaminants, including PFAS, phthalates, air pollutants, and endocrine-disrupting compounds. This acquisition is intended to continue existing larger studies to maintain data integrity and avoid protocol deviations. The EPA intends to sole source this requirement to Experimental Pathology Laboratories, Inc. (EPL) due to their specialized experience with environmental contaminants, compliance with Good Laboratory Practice regulations, and their ability to accept hand-delivered samples as a local vendor. The procurement falls under NAICS code 541714 for Research and Development in Biotechnology and PSC code AZ11. While the agency intends to award to EPL, other responsible sources may submit capability statements, proposals, or quotations by November 30, 2026. The estimated award date is December 3, 2026. All vendors must maintain a public profile in the System for Award Management and utilize the FedConnect portal for contract communications.
Tribal & Science Division Water

POSTED

4 days ago

DEADLINE

in 13 days
NAICS: 541714
New
Federal
Simulation-augmented, Real-time Platform Adaptive Seamless Trials (SURPASS)
Solicitation # ARPA-H-SOL-26-164
The Advanced Research Projects Agency for Health (ARPA-H) is soliciting proposals for the Simulation-augmented, Real-time Platform Adaptive Seamless Trials (SURPASS) program under solicitation ARPA-H-SOL-26-164. This five-year initiative aims to create a reusable blueprint for future adaptive seamless platform trials through the integration of three technical areas: a Phaseless Design Engine, Continuous Inference, and Agentic Operations. The program is divided into two stages, with Stage I focusing on capability buildout, FDA engagement, and the onboarding of at least three intervention arms over 24 months, followed by a 36-month Stage II dedicated to validation and deployment. A critical go/no-go milestone is obtaining FDA authorization for the platform Master Protocol IND and at least one investigational arm by the end of Stage I. The government intends to make multiple awards via Other Transaction Agreements to proposers offering the most advantageous solutions based on innovation, feasibility, and technical merit at reasonable prices. Eligible entities must possess a Unique Entity Identifier and active SAM registration. Proposals are submitted in a phased approach, beginning with a Solution Summary and potentially progressing to a Solution Pitch package. Performance will be measured by the successful integration of the three technical areas and the achievement of specific program metrics. All work must adhere to ICH E6(R3) Good Clinical Practice and strict regulatory standards to ensure inspection readiness and participant safety.
Advanced Research Projects Agency For Health (arpa-H)

POSTED

4 days ago

DEADLINE

in 13 days
NAICS: 541714
New
Federal
Laguna Industry Day
Solicitation # DARPA-SN-27-18
The Defense Advanced Research Projects Agency (DARPA) Biological Technologies Office is hosting a virtual Industry Day on December 9, 2026, for the Laguna program under Special Notice DARPA-SN-27-18. The program's primary objective is to develop and demonstrate integrated manufacturing approaches that convert abundant domestic feedstocks, such as sugars, ethylene, and BTX, into application-ready specialty chemical formulations. By minimizing intermediate processing steps and separations, the initiative seeks to reduce reliance on vulnerable foreign supply chains. The anticipated 36-month effort is divided into two technical areas: Make and Formulate, which focuses on developing defense-relevant specialty products from U.S. raw materials, and Model, which aims to create predictive tools to optimize the relationship between feedstocks, synthesis, and final product performance. This notice is issued for information and program planning purposes and does not constitute a formal solicitation for proposals. Interested parties must register for the Industry Day event by December 2, 2026. The program requires that resulting products meet or exceed the performance of current military materials, with deliverables including technoeconomic analyses, life cycle assessments, and commercialization strategy plans. Technical and administrative inquiries are managed by Dr. William Mounfield and can be directed to [email hidden]. A draft program solicitation is expected to be released on sam.gov prior to the Industry Day event.
Defense Advanced Research Projects Agcy

POSTED

5 days ago

DEADLINE

in 15 days

AI Contract Overview

Show more

The Smart Red Blood Cells (Smart-RBC) program solicitation (DARPA-PS-26-02) issued by the Defense Advanced Research Projects Agency (DARPA) seeks innovative proposals to engineer human red blood cells with synthetic biological circuits capable of sensing biomarkers, making decisions, and producing effector molecules to temporarily and safely alter human physiology. The program’s aims are focused on enhancing human performance and survivability, addressing use cases such as improving exercise tolerance and accelerating hemostasis. The anticipated funding totals approximately $35.1 million over a 36-month period, structured into two 18-month phases, with multiple awards expected. Proposals are solicited under Other Transaction Agreements for prototypes pursuant to 10 U.S.C. § 4022, emphasizing rapid innovation and flexible contract terms suited to advanced research projects beyond the scope of traditional FAR contracts. The solicitation requires a milestone-based approach with deliverables including technical reports, data management plans, gene editing documentation, biological circuit development, and final capability demonstrations. Deliverables and payments are tied to the accomplishment of milestones as specified in the Schedule of Milestones and Payments, and all data submissions are managed electronically via the DARPA VAULT platform. The contract incorporates specialized terms governing cybersecurity, intellectual property (patent and data rights), export controls, civil rights compliance, and prohibitions on the use of certain telecommunications equipment as required by statute and regulation. Key personnel undergo a risk-based security review to protect critical technology and intellectual property, and proposers must fully disclose and mitigate potential organizational conflicts of interest, particularly where they provide technical assistance to DARPA concurrently with performing research. Administrative requirements include mandatory registration in the System for Award Management (SAM), electronic invoicing through the Wide Area Workflow (WAWF) system, and milestone verification by DARPA’s Agreements Officer Representative (AOR). The evaluation process begins with an 8-page abstract submission reviewed non-competitively against defined criteria including innovation, technical approach, risk mitigation, and alignment with program objectives. Selectable abstracts are invited to proceed to a more detailed Oral Proposal Package (OPP) phase, which includes in-person or virtual presentations and a rigorous assessment of technical merit, government value, commercialization potential, and regulatory compliance. Awards are based on best value determinations, not solely on price, with milestone payments made contingent upon successful completion and Government acceptance of milestone deliverables. Although the contract does not specify packaging or shipping requirements, it mandates appropriate marking of proprietary and Controlled Unclassified Information (CUI) per DoD guidelines. The agreement framework reflects DAR

General Info

DARPA funds engineering synthetic red blood cells to enhance human physiology, performance, survivability.

NAICS

541714 - Research and Development in Biotechnology (except Nanobiotechnology)

Place of Performance

VA

Set-Aside

NONE

Documents

4
DOCX, High priority: read this first3 pages · presolicitation
High
DOCX, Low priority33 pages · other
Low
DOCX, Low priority2 pages · other
Low
PDF, Low priority21 pages · baa
Low

Read all 4 documents

Every page of every file, in your free workspace.

Read the documents

AI Contract Breakdown

Uniform Contract Format

Sign up to view the full breakdown with detailed analysis of each section.

View Full Breakdown

This one is closed. Find the next one like it.

Open contracts like this one, right now:

  • Chemical, Biological, Radiological, and Nuclear (CBRN) Medical Countermeasure (MCM) Participant Basic Agreement (PBA)Open now
  • DNA Sequencing ServiceOpen now, due in 20 days
See open contracts like this

Ask CLEATUS

I've read this contract. Ask me anything.

Timeline

PhaseClosed
Posted

Solicitation

Response Deadline

Deadline has passed

Submission Closed

Find active opportunities like this

Get full access to discover similar active contracts, track opportunities, and build proposals with AI assistance.

Organization & Contact Information

Show more
AgencyDepartment Of Defense → Defense Advanced Research Projects Agcy
Contacts1 person available
OfficeARLINGTON, VA, 222032114, USA
Office AddressARLINGTON, VA, 222032114, USA

Full Description

Show more
https://api.sam.gov/prod/opportunities/v1/noticedesc?noticeid=a0160217c997497c897c3320db9dcb7f

More opportunities from Department Of Defense → Defense Advanced Research Projects Agcy

Same awarding agency

NAICS: 541715
New
Federal
Altered B Proposers Day
Solicitation # DARPA-SN-27-20
The Altered B Proposers Day, issued by the Defense Advanced Research Projects Agency (DARPA) Defense Sciences Office under solicitation DARPA-SN-27-20, is an informational event designed to introduce the research community to the Altered B program vision. The program seeks foundational breakthroughs in altermagnetism to enable revolutionary low-power electronic and computational capabilities for defense and civilian applications. The effort is divided into two primary focus areas: Materials Synthesis, Processing, and Characterization, which focuses on the discovery and scaling of altermagnetic materials, and Integration and Device Fabrication, which focuses on developing functional hardware demonstrators. Key target prototypes include magnetoresistive RAM (MRAM), high-frequency signal processors, and neuromorphic computing components. This event is not a formal solicitation for proposals or abstracts, and a formal Program Announcement is anticipated for release in December 2026 via sam.gov. The Proposers Day is open to U.S. citizens, permanent residents, and foreign nationals, with specific identity verification and official visit requirements for foreign government officials. Interested parties may submit a single PDF slide for a Lightning Talk by noon on December 2, 2026, provided the content is appropriate for public release. All attendees must present valid government-issued photo identification for physical entry. Technical and administrative inquiries are directed to Program Manager Keith Whitener at [email hidden].
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

about 11 hours ago

DEADLINE

in 21 days
View Details
NAICS: 541715
New
Federal
Unison
Solicitation # DARPA-PS-27-06
The Defense Advanced Research Projects Agency (DARPA) Strategic Technology Office is soliciting proposals for Unison, a program focused on developing collaborative-autonomy approaches that jointly adapt team decision-making and communications during mission execution. The program aims to enable autonomous teams of tens to hundreds of agents to modify tactics, behaviors, and information exchange as mission complexity increases or communications become degraded. This effort is divided into two Technical Areas: Joint Co-adaptation (TA-1) and Modeling and Simulation Environment (TA-2). The core objective is to preserve mission performance while reducing communication dependence and the reasoning burden on individual agents in dynamic, resource-constrained environments. This procurement is conducted via an Other Transaction Agreement (OTA) for Prototypes under 10 U.S.C. 4022. Key requirements include CMMC Level 2 self-assessment and compliance with NIST SP 800-171 Rev 2 and DoD Instruction 5200.48 for the protection of Controlled Unclassified Information (CUI). Awards will be based on technical approach, relevant qualifications in autonomy and communications, budget realism, and the extent of government data rights. Performance is measured through a milestone-based approach with specific exit criteria, including computational tractability and repeatability. Proposals must be submitted as encrypted zip files in LaTeX format to the BAA Coordinator by the specified deadline.
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

4 days ago

DEADLINE

in 17 days
View Details

Get AI-powered intelligence on the opportunities still open

Every solicitation package arrives shredded into a compliance breakdown and matched to your past performance, with incumbent history and alerts on amendments and award.

Miguel
Hillary
Keith Deutsch
Christine

Join 750+ contractors already using CLEATUS